Carboplatin

Generic Name
Carboplatin
Brand Names
Paraplatin
Drug Type
Small Molecule
Chemical Formula
C6H12N2O4Pt
CAS Number
41575-94-4
Unique Ingredient Identifier
BG3F62OND5
Background

Carboplatin is an organoplatinum antineoplastic alkylating agent used in the treatment of advanced ovarian carcinoma. Early clinical studies of carboplatin were performed in 1982. Carboplatin was developed as an analog of cisplatin with reduced nephrotoxicity and vomiting.

Carboplatin was granted FDA approval on 3 March 1989.

Indication

Carboplatin is indicated in combination with an established combination of chemotherapeutic agents for the initial treatment of advanced ovarian carcinoma. Carboplatin is also indicated for the palliative treatment of ovarian carcinoma, recurrent after prior chemotherapy.

Associated Conditions
Advanced Cervical Cancer, Advanced Endometrial Cancer, Advanced Esophageal Cancers, Advanced Head and Neck Cancer, Advanced Melanoma, Advanced Non-Small Cell Lung Cancer (NSCLC), Advanced Ovarian Carcinoma, Advanced Sarcoma, Malignant Pleural Mesothelioma (MPM), Merkel Cell Carcinoma, Metastatic Breast Cancer, Refractory Hodgkin Lymphoma, Retinoblastoma, Thymoma, Advanced Bladder cancer, Advanced Small cell lung cancer, Advanced Testicular cancer, Advanced Thymoma, Refractory Non-Hodgkin's lymphoma
Associated Therapies
Conditioning regimens for allogeneic stem cell transplantation therapy
Clinical Trials
Related News

Paclitaxel, Carboplatin, and Radiation Therapy With or Without Adjuvant Paclitaxel and Carboplatin in Treating Patients With Stage II or Stage III Unresectable Non-Small Cell Lung Cancer

Phase 3
Conditions
Lung Cancer
First Posted Date
2004-02-11
Last Posted Date
2009-02-09
Lead Sponsor
GERCOR - Multidisciplinary Oncology Cooperative Group
Registration Number
NCT00077220
Locations
🇫🇷

Institut Sainte Catherine, Avignon, France

🇫🇷

Centre Hospitalier Bayeux, Bayeux, France

🇫🇷

Clinique Tivoli, Bordeaux, France

and more 64 locations

Repeated Bone Marrow Transplantation in Treating Women With Advanced Breast Cancer

Phase 1
Terminated
Conditions
Breast Cancer
First Posted Date
2004-02-09
Last Posted Date
2020-07-14
Lead Sponsor
Louisiana State University Health Sciences Center Shreveport
Target Recruit Count
12
Registration Number
NCT00003086
Locations
🇺🇸

Louisiana State University School of Medicine, Shreveport, Louisiana, United States

Squalamine Lactate Plus Carboplatin in Treating Patients With Recurrent or Refractory Stage III or Stage IV Ovarian Cancer

Phase 2
Conditions
Ovarian Cancer
First Posted Date
2004-02-04
Last Posted Date
2013-12-18
Lead Sponsor
Jonsson Comprehensive Cancer Center
Registration Number
NCT00021385
Locations
🇺🇸

Jonsson Comprehensive Cancer Center, UCLA, Los Angeles, California, United States

Combination Chemotherapy in Treating Patients With Recurrent Glioblastoma Multiforme

First Posted Date
2004-02-04
Last Posted Date
2013-12-04
Lead Sponsor
Atlantic Health System
Registration Number
NCT00014105
Locations
🇺🇸

Overlook Hospital, Summit, New Jersey, United States

Carboplatin and Paclitaxel With or Without ISIS 3521 in Treating Patients With Non-Small Cell Lung Cancer

Phase 3
Completed
Conditions
Lung Cancer
First Posted Date
2004-02-04
Last Posted Date
2022-12-05
Lead Sponsor
Ionis Pharmaceuticals, Inc.
Registration Number
NCT00017407
Locations
🇺🇸

Ireland Cancer Center, Cleveland, Ohio, United States

🇺🇸

ISIS Pharmaceuticals, Inc., Carlsbad, California, United States

Paclitaxel Plus Carboplatin With or Without Topotecan in Treating Patients With Stage IIB, Stage III, or Stage IV Ovarian Epithelial Cancer

Phase 3
Completed
Conditions
Fallopian Tube Cancer
Ovarian Cancer
First Posted Date
2004-02-03
Last Posted Date
2015-12-23
Lead Sponsor
AGO Study Group
Registration Number
NCT00006454
Locations
🇩🇪

Medizinische Klinik I, Dresden, Germany

🇩🇪

Christian-Albrechts University of Kiel, Kiel, Germany

🇩🇪

Zentralkrankenhaus, Bremen, Germany

and more 16 locations

Combination Chemotherapy Plus Peripheral Stem Cell Transplantation in Treating Patients With Germ Cell Tumors

First Posted Date
2004-01-27
Last Posted Date
2016-06-23
Lead Sponsor
UNICANCER
Target Recruit Count
45
Registration Number
NCT00003852
Locations
🇫🇷

Centre Jean Perrin, Clermont-Ferrand, France

🇫🇷

Centre de Lute Contre le Cancer,Georges-Francois Leclerc, Dijon, France

🇫🇷

Centre Leon Berard, Lyon, France

and more 15 locations

Combination Chemotherapy, Radiation Therapy, and Peripheral Stem Cell Transplantation in Treating Patients With Stage III or Stage IV Mantle Cell Lymphoma

Phase 1
Completed
Conditions
Lymphoma
First Posted Date
2004-01-23
Last Posted Date
2013-06-24
Lead Sponsor
Memorial Sloan Kettering Cancer Center
Target Recruit Count
24
Registration Number
NCT00003541
Locations
🇺🇸

Memorial Sloan-Kettering Cancer Center, New York, New York, United States

Combination Chemotherapy With Bone Marrow Transplantation in Treating Men With Germ Cell Tumors

First Posted Date
2004-01-15
Last Posted Date
2021-02-23
Lead Sponsor
UNICANCER
Target Recruit Count
280
Registration Number
NCT00002566
Locations
🇫🇷

Institut Gustave Roussy, Villejuif, France

Temozolomide Plus Carboplatin in Treating Patients With Recurrent Glioblastoma Multiforme

Phase 1
Withdrawn
Conditions
Brain and Central Nervous System Tumors
First Posted Date
2004-01-14
Last Posted Date
2013-07-11
Lead Sponsor
Fox Chase Cancer Center
Registration Number
NCT00021307
© Copyright 2024. All Rights Reserved by MedPath
HomeTerms & ConditionsPrivacy Policy